Polly A.  Murphy net worth and biography

Polly Murphy Biography and Net Worth

Polly A. Murphy is on the Board of Directors at Atea Pharmaceuticals. Polly is also the Chief Business Officer at UroGen Pharma.

How do I contact Polly A. Murphy?

The corporate mailing address for Dr. Murphy and other Atea Pharmaceuticals executives is , , . Atea Pharmaceuticals can also be reached via phone at 857-284-8891 and via email at [email protected]. Learn More on Polly A. Murphy's contact information.

Has Polly A. Murphy been buying or selling shares of Atea Pharmaceuticals?

Polly A. Murphy has not been actively trading shares of Atea Pharmaceuticals during the past quarter. Most recently, on Monday, December 20th, Polly A. Murphy bought 12,000 shares of Atea Pharmaceuticals stock. The stock was acquired at an average cost of $8.57 per share, with a total value of $102,840.00. Learn More on Polly A. Murphy's trading history.

Are insiders buying or selling shares of Atea Pharmaceuticals?

During the last twelve months, insiders at the sold shares 4 times. They sold a total of 86,236 shares worth more than $331,876.30. The most recent insider tranaction occured on June, 5th when CEO Jean-Pierre Sommadossi sold 1,006 shares worth more than $4,024.00. Insiders at Atea Pharmaceuticals own 17.8% of the company. Learn More about insider trades at Atea Pharmaceuticals.

Information on this page was last updated on 6/5/2024.

Polly A. Murphy Insider Trading History at Atea Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/20/2021Buy12,000$8.57$102,840.00View SEC Filing Icon  
See Full Table

Polly A. Murphy Buying and Selling Activity at Atea Pharmaceuticals

This chart shows Polly A Murphy's buying and selling at Atea Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Atea Pharmaceuticals Company Overview

Atea Pharmaceuticals logo
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $3.49
Low: $3.49
High: $3.65

50 Day Range

MA: $3.75
Low: $3.49
High: $4.04

2 Week Range

Now: $3.49
Low: $2.77
High: $4.60


227,132 shs

Average Volume

254,524 shs

Market Capitalization

$293.93 million

P/E Ratio


Dividend Yield